Advertisement
BMY vs PFE
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) delivered a strong second-quarter 2026 earnings beat with adjusted EPS of $2.04 versus estimates of $1.60 and raised full-year guidance, supporting recent stock momentum.
- Pfizer (PFE) shares trade near $25 with a high dividend yield around 6.8%, while awaiting its second-quarter 2026 results scheduled for early August.
- Over the past year, BMY has significantly outperformed PFE in total return, reflecting differences in growth portfolio execution and market positioning.
- Both companies operate in the biopharmaceutical sector with exposure to patent expirations, yet BMY’s recent pipeline and commercial execution have drawn more positive analyst attention in recent weeks.
- PFE continues to advance late-stage candidates, including positive vitiligo trial data and priority review for a prostate cancer combination therapy.
- Relative performance highlights trade-offs between BMY’s momentum-driven profile and PFE’s income-oriented appeal amid broader healthcare sector dynamics.
Introduction
Bristol-Myers Squibb (BMY) and Pfizer (PFE) represent two established players in the global biopharmaceutical industry, each navigating patent cliffs, pipeline development, and evolving market conditions. This comparison examines their recent performance, business fundamentals, and relative positioning within the healthcare sector. Institutional investors, dividend-focused traders, and those monitoring large-cap pharmaceutical exposure may find the analysis relevant when assessing portfolio allocation or sector rotation strategies. The review emphasizes verifiable developments from recent market activity while maintaining a neutral perspective on observable trends and contrasts.
Bristol-Myers Squibb (BMY) Overview and Recent Performance
Bristol-Myers Squibb (BMY) develops and commercializes medicines across oncology, immunology, and cardiovascular areas. In recent market activity, the stock has shown resilience following its second-quarter 2026 earnings release on July 30, where adjusted earnings per share reached $2.04, exceeding consensus estimates, and revenue totaled $12.97 billion. Management raised full-year guidance, citing strength in its growth portfolio. Shares have traded near the upper end of their 52-week range around $65, supported by multiple analyst price target increases. Sentiment has benefited from commercial execution and pipeline progress, though legacy product declines remain a noted factor in broader commentary. Market positioning reflects steady momentum in recent weeks amid healthcare sector rotation.
Pfizer (PFE) Overview and Recent Performance
Pfizer (PFE) focuses on innovative therapies in oncology, vaccines, and internal medicine, complemented by a substantial dividend program. In recent market activity, shares have traded around $25 amid anticipation of second-quarter 2026 results due in early August. Positive developments include late-stage trial success for LITFULO in nonsegmental vitiligo and U.S. FDA priority review for a Talzenna plus Xtandi combination in prostate cancer. The stock maintains a dividend yield near 6.8%, appealing to income-oriented participants. Performance has been more measured compared with broader peers, with the company continuing to refine its pipeline while addressing loss-of-exclusivity pressures. Recent sentiment reflects a balance between pipeline catalysts and ongoing portfolio transitions.
Trending AI Robots
Tickeron maintains a curated section called Trending AI Robots that highlights select AI trading bots from a much larger library. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers across equities, options, and other instruments. Only those demonstrating the strongest alignment with prevailing market conditions, robust risk-adjusted metrics, and consistent historical performance earn placement in the trending section. Available bots span a wide range of trading styles, timeframes, and ticker sets, with performance statistics and strategy details varying by model. Traders can review win rates, drawdowns, and other quantitative measures directly on the page. This resource provides an informational overview for market participants interested in automated strategies. Visit Trending AI Robots to explore current selections.
Head-to-Head Comparison
Bristol-Myers Squibb (BMY) and Pfizer (PFE) share exposure to the biopharmaceutical sector yet differ in recent momentum and income characteristics. BMY’s business model emphasizes oncology and immunology growth drivers that contributed to its stronger earnings surprise and guidance lift. PFE offers a higher current dividend yield but faces nearer-term earnings visibility pending its upcoming report. Relative performance over the past year favors BMY, while PFE’s valuation and yield profile may appeal to conservative income strategies. Risk factors include patent expirations for both, though BMY’s newer assets have drawn comparatively steadier analyst support in recent weeks. Market sentiment reflects these contrasts, with BMY exhibiting tighter trend consistency and PFE positioned for potential catalysts around its earnings cycle and late-stage readouts.
Tickeron AI Verdict
Based on observable factors such as recent earnings execution, trend consistency, and relative momentum, Tickeron’s AI assessment would assign a higher probabilistic weighting to Bristol-Myers Squibb (BMY) in the current environment. The company’s second-quarter beat and raised outlook provide measurable support for positioning, while Pfizer (PFE) awaits its results and continues pipeline advancement. The verdict remains probabilistic and tied to ongoing data rather than absolute forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 2 green FA rating(s).
- BMY’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 6 bullish TA indicator(s).
- BMY’s TA Score: 3 bullish, 4 bearish.
- PFE’s TA Score: 6 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +0.11% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.94% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.01%. For the same industry, the average monthly price growth was +2.37%, and the average quarterly price growth was +2.82%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+2.01% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | PFE | BMY / PFE | |
| Capitalization | 130B | 150B | 87% |
| EBITDA | 16.8B | 17.2B | 98% |
| Gain YTD | 22.085 | 11.116 | 199% |
| P/E Ratio | 14.03 | 34.62 | 41% |
| Revenue | 49.2B | 63.3B | 78% |
| Total Cash | 11.1B | N/A | - |
| Total Debt | 45.1B | 63.7B | 71% |
BMY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 83 | 100 | |
SMR RATING 1..100 | 22 | 77 | |
PRICE GROWTH RATING 1..100 | 21 | 34 | |
P/E GROWTH RATING 1..100 | 79 | 6 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as PFE (4). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's Profit vs Risk Rating (83) in the Pharmaceuticals Major industry is in the same range as PFE (100). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (77). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
BMY's Price Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as PFE (34). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (79). This means that PFE’s stock grew significantly faster than BMY’s over the last 12 months.
| BMY | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 36% | 2 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 50% |
| MACD ODDS (%) | 2 days ago 53% | 3 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 55% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 48% |
| Advances ODDS (%) | 7 days ago 55% | 7 days ago 52% |
| Declines ODDS (%) | N/A | 2 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 45% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.14% | ||
| AMGN - BMY | 57% Loosely correlated | +0.45% | ||
| PFE - BMY | 57% Loosely correlated | -1.16% | ||
| NVS - BMY | 55% Loosely correlated | -1.48% | ||
| GSK - BMY | 53% Loosely correlated | -1.18% | ||
| ABBV - BMY | 49% Loosely correlated | -0.53% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -1.16% | ||
| BMY - PFE | 57% Loosely correlated | +0.14% | ||
| MRK - PFE | 55% Loosely correlated | +1.92% | ||
| AMGN - PFE | 53% Loosely correlated | +0.45% | ||
| NVS - PFE | 51% Loosely correlated | -1.48% | ||
| BIIB - PFE | 51% Loosely correlated | +2.44% | ||
More | ||||